Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded by Wall Street Zen to "Strong-Buy" Rating

Key Points

• Kiniksa Pharmaceuticals International's stock rating has been upgraded from "buy" to a "strong-buy" by Wall Street Zen, reflecting increased confidence in the company's performance.
• The stock has seen analysts set target prices ranging from $36.00 to $54.00, with a consensus target price of $41.17.
• Kiniksa recently reported earnings that exceeded expectations, with an EPS of $0.23 against a consensus estimate of $0.18, indicating strong financial health amid robust revenues.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report issued on Sunday.

Other research analysts also recently issued reports about the company. Wedbush reiterated an "outperform" rating and issued a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Wells Fargo & Company lifted their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, July 9th. Finally, Jefferies Financial Group lifted their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $41.17.

Kiniksa Pharmaceuticals International Trading Up 0.2%

Shares of KNSA stock traded up $0.09 on Friday, reaching $37.10. 396,031 shares of the company's stock were exchanged, compared to its average volume of 411,524. Kiniksa Pharmaceuticals International has a 52 week low of $17.82 and a 52 week high of $37.34. The stock has a market capitalization of $2.75 billion, a PE ratio of 927.73 and a beta of 0.20. The company's fifty day simple moving average is $31.86 and its 200 day simple moving average is $27.08.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.18 by $0.05. The company had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 11,000 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $34.84, for a total transaction of $383,240.00. Following the completion of the sale, the chief accounting officer owned 38,011 shares of the company's stock, valued at approximately $1,324,303.24. The trade was a 22.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Thomas Malley sold 78,233 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $33.09, for a total value of $2,588,729.97. Following the sale, the director directly owned 12,546 shares of the company's stock, valued at approximately $415,147.14. This represents a 86.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 562,271 shares of company stock worth $18,716,309 in the last quarter. 53.48% of the stock is owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Institutional investors and hedge funds have recently modified their holdings of the stock. EverSource Wealth Advisors LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after buying an additional 532 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after buying an additional 568 shares during the period. Osaic Holdings Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at about $31,000. US Bancorp DE acquired a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at about $33,000. Finally, Asset Management One Co. Ltd. acquired a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at about $41,000. Institutional investors and hedge funds own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.